全文获取类型
收费全文 | 30401篇 |
免费 | 2508篇 |
国内免费 | 55篇 |
专业分类
耳鼻咽喉 | 155篇 |
儿科学 | 1112篇 |
妇产科学 | 1001篇 |
基础医学 | 4057篇 |
口腔科学 | 493篇 |
临床医学 | 4130篇 |
内科学 | 5484篇 |
皮肤病学 | 369篇 |
神经病学 | 3542篇 |
特种医学 | 560篇 |
外科学 | 2941篇 |
综合类 | 459篇 |
一般理论 | 57篇 |
预防医学 | 3639篇 |
眼科学 | 640篇 |
药学 | 2046篇 |
中国医学 | 33篇 |
肿瘤学 | 2246篇 |
出版年
2023年 | 240篇 |
2022年 | 257篇 |
2021年 | 524篇 |
2020年 | 414篇 |
2019年 | 648篇 |
2018年 | 681篇 |
2017年 | 552篇 |
2016年 | 575篇 |
2015年 | 661篇 |
2014年 | 924篇 |
2013年 | 1366篇 |
2012年 | 2013篇 |
2011年 | 2096篇 |
2010年 | 1097篇 |
2009年 | 1048篇 |
2008年 | 1836篇 |
2007年 | 1899篇 |
2006年 | 1930篇 |
2005年 | 1808篇 |
2004年 | 1788篇 |
2003年 | 1708篇 |
2002年 | 1588篇 |
2001年 | 603篇 |
2000年 | 545篇 |
1999年 | 495篇 |
1998年 | 322篇 |
1997年 | 287篇 |
1996年 | 235篇 |
1995年 | 227篇 |
1994年 | 175篇 |
1993年 | 191篇 |
1992年 | 295篇 |
1991年 | 299篇 |
1990年 | 254篇 |
1989年 | 241篇 |
1988年 | 229篇 |
1987年 | 227篇 |
1986年 | 185篇 |
1985年 | 196篇 |
1984年 | 133篇 |
1983年 | 144篇 |
1982年 | 130篇 |
1981年 | 112篇 |
1980年 | 116篇 |
1979年 | 151篇 |
1978年 | 116篇 |
1977年 | 103篇 |
1976年 | 101篇 |
1974年 | 108篇 |
1972年 | 93篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
3.
4.
5.
6.
The serrated pathway (SP) can be viewed as two parallel, but partially overlapping, arrays of colorectal precursor lesions, and their respective endpoint carcinomas, that are distinct from those of the conventional adenoma–carcinoma sequence (APC‐pathway). In this review we focus at the outset on the clinical impact, pathological features, molecular genetics and biological behaviours of the various SP cancers. Then we summarize the clinicopathological features, classification and molecular profiles of the two main precursor lesions that anchor the respective pathways: (i) sessile serrated adenoma/polyp (SSA/P), also called sessile serrated lesion (SSL), and (ii) traditional serrated adenoma (TSA). Activating mutations of the RAS–RAF–MAPK pathway initiate and sustain the lesions of the SP, and CpG island methylation of the promoter regions of tumour suppressor and DNA repair genes play the major role in their neoplastic progression. The SP includes microsatellite stable (MSS) carcinomas that are among the most biologically aggressive colorectal carcinomas (CRC), and also accounts for the great preponderance of sporadic hypermutated, mismatch repair (MMR)‐deficient or microsatellite instable (MSI) CRC. The identification, removal and appropriate classification of at‐risk SP precursors and surveillance of individuals who harbour these lesions present a challenge and opportunity for CRC prevention and mortality reduction. 相似文献
7.
8.
9.
10.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献